Q4 2024 Hologic Inc Earnings Call Transcript
Key Points
- Hologic Inc (HOLX) reported total revenue of $987.9 million for the fourth quarter, exceeding the high end of their guidance range.
- The company's molecular diagnostics business grew 9% excluding COVID, demonstrating strong growth and resilience.
- Hologic Inc (HOLX) maintained a 30% operating margin, placing it in the top tier of its peer group.
- The company successfully executed its M&A strategy with acquisitions like Endo Matics and Gyno SOIC, enhancing its global portfolio.
- Hologic Inc (HOLX) announced a new $250 million accelerated share repurchase program, reflecting strong capital allocation and shareholder value focus.
- The company faced a 54.9% decrease in revenue from its Skeletal business due to a temporary stop ship, impacting overall performance.
- Hologic Inc (HOLX) anticipates headwinds in the first half of fiscal 2025 due to IV fluid shortages affecting surgical and breast procedures.
- The breast health segment is expected to experience slower growth due to the anticipation of a new gantry launch.
- The company is planning conservatively around the respiratory season, which could impact revenue from respiratory assays.
- NovaSure, a part of the surgical business, is experiencing a decline in the U.S. market due to alternative treatments becoming more prevalent.
Good afternoon and welcome to the hologics fourth quarter, fiscal 2024 earnings conference call. My name is Shelley and I am your operator for today's call.
Today's conference is being recorded. All lines have been placed on mute. I would now like to introduce Ryan Simon, Vice President, investor relations to begin the call.
Thank you, Shelley. Good afternoon and thank you for joining hologic's fourth quarter. Fiscal 2024 earnings call with me today are Steve Macmillan, the company's Chairman, President and Chief Executive Officer Essex Mitchell, our Chief Operating Officer and Carlene Overton, our Chief Financial Officer, our fourth quarter press release is available now on the investors section of our website. We will also post our prepared remarks to our website shortly after we deliver them and a replay of this call will be available on our website for the next 30 days before we begin. We would like to inform you that certain statements we make today will be forward-looking these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
